Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
Identifieur interne : 000045 ( Main/Exploration ); précédent : 000044; suivant : 000046Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
Auteurs : Roman Prymula [République tchèque] ; Dorothee Kieninger [Allemagne] ; Emmanuel Feroldi [France] ; Emilia Jordanov [États-Unis] ; Siham B'Chir [France] ; Xavier Dacosta [États-Unis]Source :
- The Pediatric infectious disease journal [ 1532-0987 ] ; 2018.
Descripteurs français
- KwdFr :
- Allemagne (MeSH), Anatoxine tétanique (administration et posologie), Anatoxine tétanique (immunologie), Anticorps antibactériens (sang), Anticorps antiviraux (sang), Calendrier vaccinal (MeSH), Femelle (MeSH), Humains (MeSH), Immunogénicité des vaccins (MeSH), Mâle (MeSH), Nourrisson (MeSH), Nouveau-né (MeSH), Rappel de vaccin (MeSH), République tchèque (MeSH), Suspensions (administration et posologie), Vaccin antipoliomyélitique inactivé (administration et posologie), Vaccin antipoliomyélitique inactivé (immunologie), Vaccination (MeSH), Vaccins anti-Haemophilus (administration et posologie), Vaccins anti-Haemophilus (immunologie), Vaccins anti-hépatite B (administration et posologie), Vaccins anti-hépatite B (immunologie), Vaccins combinés (administration et posologie), Vaccins combinés (immunologie), Vaccins diphtérique tétanique coquelucheux acellulaires (administration et posologie), Vaccins diphtérique tétanique coquelucheux acellulaires (immunologie).
- MESH :
- administration et posologie : Anatoxine tétanique, Suspensions, Vaccin antipoliomyélitique inactivé, Vaccins anti-Haemophilus, Vaccins anti-hépatite B, Vaccins combinés, Vaccins diphtérique tétanique coquelucheux acellulaires.
- immunologie : Anatoxine tétanique, Vaccin antipoliomyélitique inactivé, Vaccins anti-Haemophilus, Vaccins anti-hépatite B, Vaccins combinés, Vaccins diphtérique tétanique coquelucheux acellulaires.
- sang : Anticorps antibactériens, Anticorps antiviraux.
- Allemagne, Calendrier vaccinal, Femelle, Humains, Immunogénicité des vaccins, Mâle, Nourrisson, Nouveau-né, Rappel de vaccin, République tchèque, Vaccination.
- Wicri :
- geographic : République tchèque, Allemagne.
English descriptors
- KwdEn :
- Antibodies, Bacterial (blood), Antibodies, Viral (blood), Czech Republic (MeSH), Diphtheria-Tetanus-acellular Pertussis Vaccines (administration & dosage), Diphtheria-Tetanus-acellular Pertussis Vaccines (immunology), Female (MeSH), Germany (MeSH), Haemophilus Vaccines (administration & dosage), Haemophilus Vaccines (immunology), Hepatitis B Vaccines (administration & dosage), Hepatitis B Vaccines (immunology), Humans (MeSH), Immunization Schedule (MeSH), Immunization, Secondary (MeSH), Immunogenicity, Vaccine (MeSH), Infant (MeSH), Infant, Newborn (MeSH), Male (MeSH), Poliovirus Vaccine, Inactivated (administration & dosage), Poliovirus Vaccine, Inactivated (immunology), Suspensions (administration & dosage), Tetanus Toxoid (administration & dosage), Tetanus Toxoid (immunology), Vaccination (MeSH), Vaccines, Combined (administration & dosage), Vaccines, Combined (immunology).
- MESH :
- chemical , administration & dosage : Diphtheria-Tetanus-acellular Pertussis Vaccines, Haemophilus Vaccines, Hepatitis B Vaccines, Poliovirus Vaccine, Inactivated, Suspensions, Tetanus Toxoid, Vaccines, Combined.
- chemical , blood : Antibodies, Bacterial, Antibodies, Viral.
- chemical , immunology : Diphtheria-Tetanus-acellular Pertussis Vaccines, Haemophilus Vaccines, Hepatitis B Vaccines, Poliovirus Vaccine, Inactivated, Tetanus Toxoid, Vaccines, Combined.
- geographic : Czech Republic, Germany.
- Female, Humans, Immunization Schedule, Immunization, Secondary, Immunogenicity, Vaccine, Infant, Infant, Newborn, Male, Vaccination.
Abstract
To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with PCV13. Noninferiority (group 1 versus group 2) was tested postprimary series for seroprotection rates (anti-HB and anti-PRP) and vaccine response rates (anti-pertussis toxin and anti-filamentous hemagglutinin). Safety was assessed by parental reports. Noninferiority was demonstrated with the lower bound of the 95% confidence interval for the difference (group 1 to group 2) being > -10% for each comparison. Primary series immune responses were high for all antigens and similar in each group. Prebooster antibody persistence was good, and there was a strong anamnestic response, both being similar for the investigational and control vaccines. Responses to PCV13 and rotavirus vaccine were similar in each group. There were no safety concerns. These data support the use of the DTaP-IPV-HB-PRP-T vaccine in a 2, 3, 4 month schedule without a birth dose of HB vaccine, with a booster dose in the second year of life administered with routine childhood vaccines.
DOI: 10.1097/INF.0000000000002109
PubMed: 29762363
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.</title><author><name sortKey="Prymula, Roman" sort="Prymula, Roman" uniqKey="Prymula R" first="Roman" last="Prymula">Roman Prymula</name><affiliation wicri:level="1"><nlm:affiliation>From the Charles University Faculty of Medicine, Hradec Kralove, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>From the Charles University Faculty of Medicine, Hradec Kralove</wicri:regionArea><wicri:noRegion>Hradec Kralove</wicri:noRegion></affiliation></author><author><name sortKey="Kieninger, Dorothee" sort="Kieninger, Dorothee" uniqKey="Kieninger D" first="Dorothee" last="Kieninger">Dorothee Kieninger</name><affiliation wicri:level="1"><nlm:affiliation>Johannes Gutenberg-Universität Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johannes Gutenberg-Universität Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Feroldi, Emmanuel" sort="Feroldi, Emmanuel" uniqKey="Feroldi E" first="Emmanuel" last="Feroldi">Emmanuel Feroldi</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi Pasteur</wicri:regionArea></affiliation></author><author><name sortKey="Jordanov, Emilia" sort="Jordanov, Emilia" uniqKey="Jordanov E" first="Emilia" last="Jordanov">Emilia Jordanov</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Sanofi Pasteur, Swiftwater</wicri:cityArea></affiliation></author><author><name sortKey="B Chir, Siham" sort="B Chir, Siham" uniqKey="B Chir S" first="Siham" last="B'Chir">Siham B'Chir</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi Pasteur</wicri:regionArea></affiliation></author><author><name sortKey="Dacosta, Xavier" sort="Dacosta, Xavier" uniqKey="Dacosta X" first="Xavier" last="Dacosta">Xavier Dacosta</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Sanofi Pasteur, Swiftwater</wicri:cityArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2018">2018</date><idno type="RBID">pubmed:29762363</idno><idno type="pmid">29762363</idno><idno type="doi">10.1097/INF.0000000000002109</idno><idno type="wicri:Area/Main/Corpus">000034</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000034</idno><idno type="wicri:Area/Main/Curation">000034</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000034</idno><idno type="wicri:Area/Main/Exploration">000034</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.</title><author><name sortKey="Prymula, Roman" sort="Prymula, Roman" uniqKey="Prymula R" first="Roman" last="Prymula">Roman Prymula</name><affiliation wicri:level="1"><nlm:affiliation>From the Charles University Faculty of Medicine, Hradec Kralove, Czech Republic.</nlm:affiliation><country xml:lang="fr">République tchèque</country><wicri:regionArea>From the Charles University Faculty of Medicine, Hradec Kralove</wicri:regionArea><wicri:noRegion>Hradec Kralove</wicri:noRegion></affiliation></author><author><name sortKey="Kieninger, Dorothee" sort="Kieninger, Dorothee" uniqKey="Kieninger D" first="Dorothee" last="Kieninger">Dorothee Kieninger</name><affiliation wicri:level="1"><nlm:affiliation>Johannes Gutenberg-Universität Mainz, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Johannes Gutenberg-Universität Mainz</wicri:regionArea></affiliation></author><author><name sortKey="Feroldi, Emmanuel" sort="Feroldi, Emmanuel" uniqKey="Feroldi E" first="Emmanuel" last="Feroldi">Emmanuel Feroldi</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi Pasteur</wicri:regionArea></affiliation></author><author><name sortKey="Jordanov, Emilia" sort="Jordanov, Emilia" uniqKey="Jordanov E" first="Emilia" last="Jordanov">Emilia Jordanov</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Sanofi Pasteur, Swiftwater</wicri:cityArea></affiliation></author><author><name sortKey="B Chir, Siham" sort="B Chir, Siham" uniqKey="B Chir S" first="Siham" last="B'Chir">Siham B'Chir</name><affiliation wicri:level="1"><nlm:affiliation>Sanofi Pasteur, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Sanofi Pasteur</wicri:regionArea></affiliation></author><author><name sortKey="Dacosta, Xavier" sort="Dacosta, Xavier" uniqKey="Dacosta X" first="Xavier" last="Dacosta">Xavier Dacosta</name><affiliation wicri:level="2"><nlm:affiliation>Sanofi Pasteur, Swiftwater, PA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Sanofi Pasteur, Swiftwater</wicri:cityArea></affiliation></author></analytic><series><title level="j">The Pediatric infectious disease journal</title><idno type="eISSN">1532-0987</idno><imprint><date when="2018" type="published">2018</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies, Bacterial (blood)</term><term>Antibodies, Viral (blood)</term><term>Czech Republic (MeSH)</term><term>Diphtheria-Tetanus-acellular Pertussis Vaccines (administration & dosage)</term><term>Diphtheria-Tetanus-acellular Pertussis Vaccines (immunology)</term><term>Female (MeSH)</term><term>Germany (MeSH)</term><term>Haemophilus Vaccines (administration & dosage)</term><term>Haemophilus Vaccines (immunology)</term><term>Hepatitis B Vaccines (administration & dosage)</term><term>Hepatitis B Vaccines (immunology)</term><term>Humans (MeSH)</term><term>Immunization Schedule (MeSH)</term><term>Immunization, Secondary (MeSH)</term><term>Immunogenicity, Vaccine (MeSH)</term><term>Infant (MeSH)</term><term>Infant, Newborn (MeSH)</term><term>Male (MeSH)</term><term>Poliovirus Vaccine, Inactivated (administration & dosage)</term><term>Poliovirus Vaccine, Inactivated (immunology)</term><term>Suspensions (administration & dosage)</term><term>Tetanus Toxoid (administration & dosage)</term><term>Tetanus Toxoid (immunology)</term><term>Vaccination (MeSH)</term><term>Vaccines, Combined (administration & dosage)</term><term>Vaccines, Combined (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Allemagne (MeSH)</term><term>Anatoxine tétanique (administration et posologie)</term><term>Anatoxine tétanique (immunologie)</term><term>Anticorps antibactériens (sang)</term><term>Anticorps antiviraux (sang)</term><term>Calendrier vaccinal (MeSH)</term><term>Femelle (MeSH)</term><term>Humains (MeSH)</term><term>Immunogénicité des vaccins (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Nouveau-né (MeSH)</term><term>Rappel de vaccin (MeSH)</term><term>République tchèque (MeSH)</term><term>Suspensions (administration et posologie)</term><term>Vaccin antipoliomyélitique inactivé (administration et posologie)</term><term>Vaccin antipoliomyélitique inactivé (immunologie)</term><term>Vaccination (MeSH)</term><term>Vaccins anti-Haemophilus (administration et posologie)</term><term>Vaccins anti-Haemophilus (immunologie)</term><term>Vaccins anti-hépatite B (administration et posologie)</term><term>Vaccins anti-hépatite B (immunologie)</term><term>Vaccins combinés (administration et posologie)</term><term>Vaccins combinés (immunologie)</term><term>Vaccins diphtérique tétanique coquelucheux acellulaires (administration et posologie)</term><term>Vaccins diphtérique tétanique coquelucheux acellulaires (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diphtheria-Tetanus-acellular Pertussis Vaccines</term><term>Haemophilus Vaccines</term><term>Hepatitis B Vaccines</term><term>Poliovirus Vaccine, Inactivated</term><term>Suspensions</term><term>Tetanus Toxoid</term><term>Vaccines, Combined</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Bacterial</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Diphtheria-Tetanus-acellular Pertussis Vaccines</term><term>Haemophilus Vaccines</term><term>Hepatitis B Vaccines</term><term>Poliovirus Vaccine, Inactivated</term><term>Tetanus Toxoid</term><term>Vaccines, Combined</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Czech Republic</term><term>Germany</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Anatoxine tétanique</term><term>Suspensions</term><term>Vaccin antipoliomyélitique inactivé</term><term>Vaccins anti-Haemophilus</term><term>Vaccins anti-hépatite B</term><term>Vaccins combinés</term><term>Vaccins diphtérique tétanique coquelucheux acellulaires</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anatoxine tétanique</term><term>Vaccin antipoliomyélitique inactivé</term><term>Vaccins anti-Haemophilus</term><term>Vaccins anti-hépatite B</term><term>Vaccins combinés</term><term>Vaccins diphtérique tétanique coquelucheux acellulaires</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antibactériens</term><term>Anticorps antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Immunization, Secondary</term><term>Immunogenicity, Vaccine</term><term>Infant</term><term>Infant, Newborn</term><term>Male</term><term>Vaccination</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Allemagne</term><term>Calendrier vaccinal</term><term>Femelle</term><term>Humains</term><term>Immunogénicité des vaccins</term><term>Mâle</term><term>Nourrisson</term><term>Nouveau-né</term><term>Rappel de vaccin</term><term>République tchèque</term><term>Vaccination</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>République tchèque</term><term>Allemagne</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with PCV13. Noninferiority (group 1 versus group 2) was tested postprimary series for seroprotection rates (anti-HB and anti-PRP) and vaccine response rates (anti-pertussis toxin and anti-filamentous hemagglutinin). Safety was assessed by parental reports. Noninferiority was demonstrated with the lower bound of the 95% confidence interval for the difference (group 1 to group 2) being > -10% for each comparison. Primary series immune responses were high for all antigens and similar in each group. Prebooster antibody persistence was good, and there was a strong anamnestic response, both being similar for the investigational and control vaccines. Responses to PCV13 and rotavirus vaccine were similar in each group. There were no safety concerns. These data support the use of the DTaP-IPV-HB-PRP-T vaccine in a 2, 3, 4 month schedule without a birth dose of HB vaccine, with a booster dose in the second year of life administered with routine childhood vaccines.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29762363</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1532-0987</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2018</Year><Month>08</Month></PubDate></JournalIssue><Title>The Pediatric infectious disease journal</Title><ISOAbbreviation>Pediatr. Infect. Dis. J.</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.</ArticleTitle><Pagination><MedlinePgn>823-830</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/INF.0000000000002109</ELocationID><Abstract><AbstractText>To support a fully liquid, diphtheria (D)-tetanus (T)-acellular pertussis (aP)-inactivated poliovirus (IPV)-hepatitis B (HB)-Haemophilus influenzae b (PRP-T) vaccine in Europe using a 2, 3, 4 month primary series and a booster at 11-15 months of age. Phase III, randomized, observer-blind studies in Germany and the Czech Republic. Participants who had not received HB vaccine were randomized to a 2, 3, 4 month primary series of DTaP-IPV-HB-PRP-T (group 1; N = 266) or a reconstituted DTaP-HB-IPV//PRP-T comparator (group 2; N = 263) and a booster of the same vaccine. Pneumococcal vaccine (PCV13) and rotavirus vaccine were coadministered at 2, 3, 4 months, and the booster was coadministered with PCV13. Noninferiority (group 1 versus group 2) was tested postprimary series for seroprotection rates (anti-HB and anti-PRP) and vaccine response rates (anti-pertussis toxin and anti-filamentous hemagglutinin). Safety was assessed by parental reports. Noninferiority was demonstrated with the lower bound of the 95% confidence interval for the difference (group 1 to group 2) being > -10% for each comparison. Primary series immune responses were high for all antigens and similar in each group. Prebooster antibody persistence was good, and there was a strong anamnestic response, both being similar for the investigational and control vaccines. Responses to PCV13 and rotavirus vaccine were similar in each group. There were no safety concerns. These data support the use of the DTaP-IPV-HB-PRP-T vaccine in a 2, 3, 4 month schedule without a birth dose of HB vaccine, with a booster dose in the second year of life administered with routine childhood vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prymula</LastName><ForeName>Roman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Charles University Faculty of Medicine, Hradec Kralove, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kieninger</LastName><ForeName>Dorothee</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Johannes Gutenberg-Universität Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feroldi</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordanov</LastName><ForeName>Emilia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur, Swiftwater, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>B'Chir</LastName><ForeName>Siham</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DaCosta</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Sanofi Pasteur, Swiftwater, PA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Infect Dis J</MedlineTA><NlmUniqueID>8701858</NlmUniqueID><ISSNLinking>0891-3668</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000907">Antibodies, Bacterial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D022681">Diphtheria-Tetanus-acellular Pertussis Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018073">Haemophilus Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C055753">Haemophilus influenza type b polysaccharide vaccine-tetanus toxin conjugate</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017325">Hepatitis B Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011054">Poliovirus Vaccine, Inactivated</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013535">Suspensions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013745">Tetanus Toxoid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017778">Vaccines, Combined</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000907" MajorTopicYN="N">Antibodies, Bacterial</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018153" MajorTopicYN="N" Type="Geographic">Czech Republic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D022681" MajorTopicYN="N">Diphtheria-Tetanus-acellular Pertussis Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018073" MajorTopicYN="N">Haemophilus Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017325" MajorTopicYN="N">Hepatitis B Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071497" MajorTopicYN="Y">Immunogenicity, Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011054" MajorTopicYN="N">Poliovirus Vaccine, Inactivated</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013535" MajorTopicYN="N">Suspensions</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013745" MajorTopicYN="N">Tetanus Toxoid</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017778" MajorTopicYN="N">Vaccines, Combined</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29762363</ArticleId><ArticleId IdType="doi">10.1097/INF.0000000000002109</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Allemagne</li><li>France</li><li>République tchèque</li><li>États-Unis</li></country><region><li>Pennsylvanie</li></region></list><tree><country name="République tchèque"><noRegion><name sortKey="Prymula, Roman" sort="Prymula, Roman" uniqKey="Prymula R" first="Roman" last="Prymula">Roman Prymula</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Kieninger, Dorothee" sort="Kieninger, Dorothee" uniqKey="Kieninger D" first="Dorothee" last="Kieninger">Dorothee Kieninger</name></noRegion></country><country name="France"><noRegion><name sortKey="Feroldi, Emmanuel" sort="Feroldi, Emmanuel" uniqKey="Feroldi E" first="Emmanuel" last="Feroldi">Emmanuel Feroldi</name></noRegion><name sortKey="B Chir, Siham" sort="B Chir, Siham" uniqKey="B Chir S" first="Siham" last="B'Chir">Siham B'Chir</name></country><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Jordanov, Emilia" sort="Jordanov, Emilia" uniqKey="Jordanov E" first="Emilia" last="Jordanov">Emilia Jordanov</name></region><name sortKey="Dacosta, Xavier" sort="Dacosta, Xavier" uniqKey="Dacosta X" first="Xavier" last="Dacosta">Xavier Dacosta</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeAllemagneV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000045 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000045 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeAllemagneV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:29762363
|texte= Immunogenicity and Safety of Primary and Booster Vaccinations of a Fully Liquid DTaP-IPV-HB-PRP-T Hexavalent Vaccine in Healthy Infants and Toddlers in Germany and the Czech Republic.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:29762363" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeAllemagneV4
| This area was generated with Dilib version V0.6.35. |  |